Strategic Questions:
Pages 22-24 are interesting inclusions.
If on (page 22) the argument is that the move post GFC is from M&A action to "shared risk" through licensing the preclinical product (page 23) and the upfronts are of the order demonstrated. Then, with a MC of only 33 million, why wouldn't the prudent course and first mover advantage go to the Big Pharma with an offer of, say, double today's price? Let's triple that offer, and compare it to the figures in the Deal values on page 23. 100 million is small potatoes for Big Pharma.
Wouldn't you just buy the lot? Forget licensing?
I can't see the value in the licensing case from the Pharma perspective while the MC for PYC is this low.
With PYC's library and discovery engine, MYC data in vivo and 7.5% of Phoremost... this is M&A territory for mine.
Thoughts?
Strategic Questions: Pages 22-24 are interesting inclusions. If...
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
-0.005(3.70%) |
Mkt cap ! $606.5M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 14.0¢ | 12.5¢ | $636.3K | 4.831M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 618016 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 499245 | 2 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| PYC (ASX) Chart |